Dr. Teresa Borrás is an ocular molecular biologist with an interest in gene therapy. She received her master's degree in biology from the University of Madrid, Spain and her doctorate in molecular biology via a collaborative program between the University of Madrid and Purdue University, Indiana. She studied regulation of lens gene expression at the National Eye Institute and led her laboratory to the identification of the mutation responsible for hereditary cataracts in an animal model. She directed the research division of an ophthalmic pharmaceutical company in Barcelona, Spain with an interest in glaucoma drugs. She is currently a professor of ophthalmology at the University of North Carolina at Chapel Hill.

Dr. Borrás is a member of the scientific advisory and editorial boards of scientific associations and has organized numerous national and international symposia. She was a recipient of the Jules and Doris Stein Professorship Award from Research to Prevent Blindness and the Association of International Glaucoma Societies Award for breakthroughs in glaucoma research. Her research, funded by the National Institutes of Health, is mainly focused on the search for alternative, long-term treatments of glaucoma with the use of gene therapy. She has pioneered new strategies for delivering genes to the eye and identified several candidate genes with good potential to reduce intraocular pressure. Her goals are to be able to provide the molecular basis onto which new efficient and safer gene/drugs for glaucoma can be developed.